Cheap Cialis Blogger | Search results for "statements"

Mid John Perkins talks nearby the church, different of the first elements he is inherent to slang extensively is the principle of relocation. It is one of the foundational statements of his display of the church conjointly ministry. It represents a broader proposition betwixt Protestants, Baptists, and Evangelicals to suitable the plan of the parish since ecclesiology. What difference would it compose over your church if it took its primary score to be the earshot fix the superstructure is located? What if the associates of the church garden variety the whoop to delay tween this situation amid freight of their discipleship? I've written a few Also things attainable these quandarys forth the tract world as it is in obliteration. generic cialis buy cheap cialis buy cilais cialis

Tags: church, cialis, ecclesiology, buy, relocation

Mid physicians become licensed to currency medicine, they must outlast to make port informed regarding the wide strain of treatments including plans feasible to their patients. To ensure this doctors outlive informed, it is condign this they accommodate “continuing medical technique,” which theoretically keeps physicians updated nearby the latest developments mid their work rural seat. So far, so good. But what, exactly, is continuing medical drilling (CME)? As I will describe in this post and likely others to come, continuing medical education is close to a farce, as the “education” more closely resembles advertising than it does any recognizable form of education. As an illustration, let’s begin with continuing education via professional journals. What could be a better source of information than a medical journal, right? These journals are supposedly the beacons of science, yet they prostitute their standards in a manner that leads to the miseducation of physicians, which likely leads to their prescription of more expensive (and at times, more risky) treatments that have few, if any benefits over older treatments. Case in Point: Journal of Clinical Psychiatry. JCP regularly offers CME credits through what can best be labeled as extremely brief correspondence courses. By reading a couple of articles, then answering a few questions, doctors receive valuable CME credits, which are then used to maintain a doctor’s license. JCP is far from the only journal which participates in this practice. CME Standards: CME material is not subjected to the same peer review process as are regular articles. Though certainly flawed, the peer review process at least ensures that a group of academic researchers has the chance to evaluate the merits of a study to determine whether it should be published in a journal. One of the standards regarding the commercial sponsorship of CME states The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. When reviewing the example below, think about how loosely the above standard is enforced (read: not at all). An Example -- Transcranial Magnetic Stimulation (TMS) : In the February 2007 supplement to the Journal of Clinical Psychiatry, one of the CME options, that appears quite ironically under the heading of “Academic Highlights,” is titled: Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression. The article summarizes “highlights” from a “teleconference series” that was held in August and September 2006. The article was “prepared by the CME Institute of Physicians Postgraduate Press, Inc., and was supported by an educational grant from Neuronetics, Inc.” The teleconferences were chaired by Alan Schatzberg of Stanford and the faculty at these teleconferencs were: Mark Demitrack of Neuronetics [which manufactures the NeuroStar TMS device], John O’Reardon of the U of Pennsylvania, Elliot Richeslson of the Mayo Clinic, and Michael Thase of the University of Pittsburgh. Context: When these “teleconferences” occurred, Neuronetics’ TMS treatment was under review by the FDA as a potential treatment for depression. At least one academic reviewer had concluded that the evidence favoring TMS was pretty weak, but the data were mixed, with some research showing favorable findings. Much was at stake for Neuronetics, as FDA approval could open up a sizable market for their product. In January 2007, the FDA rejected the TMS application of Neuronetics due to weak efficacy data. Faculty: In the publication, Demitrack is listed as “faculty” – how can the Vice President and Chief Medical Officer of Neuronetics who holds no academic appointment be listed as a “faculty” member? Conflicts of Interest: Each member of the “faculty” whose names appear on this article is described as having some financial interest in Neuronetics, as a consultant, employee, shareholder, and/or recipient of research funding. Thus, each faculty member has something to lose financially if Neuronetics TMS treatment does not receive approval. Should Neuronetics falter financially, the company would be less able to fund research would show a decreasing stock value, and would have less cash to offer consultants. While I am fairly certain that most, if not all of the authors, lacked nefarious interests, it is important to note that there was not a single independent voice on the panel. In CME articles such as this, however, this is just par for the course. Introductory Advert: In the overview section that serves as the introduction to the piece, each speaker was paraphrased. Demitrack (Chief Medical Officer of Neuronetics) was paraphrased as saying: Transcranial magnetic stimulation has shown promise within the device-based platform of interventions because it is an effective, noninvasive procedure; however, at the present time, TMS therapy has not yet received U.S. Food and Drug Administration approval. This statement basically wags a finger at the FDA for dragging its feet on the approval of TMS. Sounds right on script for what a “faculty member”, er, company VP should be saying about his product, right? Richelson is paraphrased as saying: Modulating neurotransmission to specific brain areas through highly focused magnetic pulses (rTMS) may reduce or even eliminate the depressive symptoms associated with specific brain areas. This statement goes well beyond the data – there is no hard data showing conclusively that any treatment really eliminates the depressive symptoms associated with specific areas of the brain. However, such statements suggest that TMS is firmly backed by science – it can go to specific areas of the brain and fix them! Just newer version of the hackneyed chemical imbalance theory of depression – we know exactly what is wrong with your brain and our treatment can fix it. Same story, different treatment. Body of Article: The article suggests that TMS should be considered as a treatment option for depressed patients who have not seen improvement in symptoms after trying a couple of different medications among other points. My favorite statement in the article was based on comments from “faculty member" Demitrack: TMS seems to provide the promise of at least equivalent efficacy and, in some instances, perhaps better efficacy and an improved tolerability profile compared with continued, more complex pharmacotherapy. His statement is very speculative – there is no research directly comparing medication (or psychotherapy) to TMS, but that did not get in the way of his speculation. It should be made clear that I am clearly not stumping for drug treatment here – I have written on several occasions about the limitations of drug treatment for depression (1, 2, 3, 4, 5). What I am saying is that Demitrack’s conjecture does not belong in an article that counts toward educating physicians. Take the Test: When done with the infomercial, er, article, all a physician needs to do is fill out the enclosed test (it’s an open book test, so I imagine everyone passes) and mail it in. Physicians can even complete the test online. Summary: This is just one CME article of many – most of them follow the same general template. They are funded by a sponsoring company, which also funds the “independent” academic authors. In some cases, including this one, an employee of the sponsoring company is also featured prominently. A medical writer may then write up much or all of the article. How does advertising such as this, which masquerades as science, help to educate physicians? Physicians end up with the idea that unproven treatments are efficacious, unsafe treatments are fine and dandy, and that medicine continues to progress at breakneck speed, producing new treatments that are much better than their older counterparts. And this helps patients… HOW?

Tags: treatment, article, tms, cme, style

An article entitled THE IMPACT OF WORLD WAR I ON PRESENT DAY PATENT ISSUES for publication in the February 2005 issue of Intellectual Property Today discusses points about Merck v. Integra. Separately, it addresses points about "getting it wrong" in various publications: On January 10, as a result of an internal investigation over the Bush/National Guard story, CBS fired Mary Mapes, producer of the report. Josh Howard, executive producer of "60 Minutes Wednesday," his top deputy Mary Murphy, and senior vice president Betsy West were asked to resign. The person who presented the report to the public, Dan Rather, was not fired. The authenticity of the relied-upon documents was quickly questioned after the airing of the report. An ensuing issue was the defense of the report against critics for a period of about twelve days, although no underlying analysis of the document examiners and sources was undertaken during that time period. In the scandal involving false research reports of Bell Lab's Jan-Hendrik Schon, criticism of the underlying science was ignored for months, with Schon finally caught by his use of duplicate graphs, rather than through recognition by outsiders of his presentation of false results. Only Schon was fired, with no action taken against his supervisors, his co-authors, or the publishers of his work. Various law reviews publish completely false statements and indefinitely ignore inquiries questioning them. The resulting folklore becomes embedded in the legal academic community. ***** Speaking of law reviews, many discuss the Merck v. Integra case. In 30 Wm. Mitchell L. Rev. 1059 (2004), Kevin Sandstrom states: This note argues Integra Lifesciences I, Ltd. v. Merck KGaA should be overturned to allow the use of a patented drug to create different derivative products or to compare and evaluate a new product against the latest patented standard. Part II describes the common law experimental use exemption and the FDA approval safe harbor provision. n11 Part III reviews the facts, holding, and dissent in Integra. n12 Part IV analyzes Integra in light of the experimental use exemption and FDA approval safe harbor provision. n13 Finally, this note concludes by proposing that the experimental use exemption to patent infringement should be broadened to allow all scientific research on patented subject matter to comport with the patent specification's full disclosure requirement and further the patent law principles of promoting innovation and rapid technological development. n14 In 2004 Wis. L. Rev. 81, Katherine J. Strandburg states: This Article contends that there are general reasons to believe that a well-designed experimental-use exemption from infringement liability can promote faster cumulative technological progress without significantly diminishing incentives to invest in the original invention. This happy result is possible in part because the impact of some types of experimental use on inventions that are easily copied from their commercial embodiments, which I call self-disclosing inventions, is different from the effect on inventions that can be marketed without revealing the inventive ideas behind them, which I call non-self-disclosing inventions. This Article explains that the experimental-use exemption can be designed to take advantage of this differential impact without any need for patent examiners or courts to determine explicitly whether a particular invention is self-disclosing or non-self-disclosing. (...) This Article supports Mueller's proposal [76 Wash. L. Rev. 1 (2001)] for a limited exemption for "experimenting with" research tools that compensates the patentee for use of the tool through a compulsory licensing requirement. n40 However, after examining how best to separate a patentee's need to recoup investment from a socially detrimental attempt to maintain a stranglehold on research results and considering some criticisms of compulsory licensing proposals, I would modify the compulsory licensing proposal. I suggest a two-term system for research tool patents: an initial period of complete exclusivity followed by a period of compulsory licensing. *** Rochelle Dreyfuss in 46 Ariz. L. Rev. 457, states: I can imagine circumstances where patentees would rationally refuse to license. First, the argument that patentees will license is strongly dependent on the relationship between the improvement and the pioneer patent. Specifically, it requires that practicing the improvement entails the practice of the pioneer patent as well. In some fields - biotech is a prime example - this relationship is not necessarily present, even in cases where the pioneer patentee is in the same business as the so-called improver. While the patented invention may serve as an end product, its significance to the researcher may be that it helps find the improvement. Once it is found, the new product's manufacture or use will not necessarily infringe. In Integra, for instance, the patented invention was used by the infringer only as a screen. Once a drug that halts tumor growth is identified, the screen would never be needed again in connection with that drug. In such cases, the improvers' work will not accrue to the benefit of the pioneer patentee. In some cases, the improver may even discover a product that supercedes something the pioneer is selling. Certainly, it is not irrational to refuse to license somebody who would cannibalize your market. Indeed, this is a scenario that the Federal Trade Commission worries about in other contexts. n42 Second, a rational patentee might decide to climb the innovation ladder (that is, develop products) slowly, milking each market before progressing to the next one. Licensing others could interfere with this plan. Again, this concern is familiar. It has surfaced in patent cases from time to time. n43 Finally, as Eisenberg has argued, when an invention's potentials are difficult to evaluate, risk-averse patentees may prefer to wait to license until the significance of the patented invention is clarified. n44 There are also some who would argue against a rule that creates special benefits for academia on the theory that the Federal Circuit is right to treat universities like commercial actors. Research universities often have large endowments; they attract very ambitious people; they are, in fact, big businesses. Again, I do not agree. There may be substantial wealth in university endowments, but much of it is tied up in the school's teaching mission, and thus cannot be easily deployed for commercial objectives. Human resources are similarly less fungible in universities than in commercial firms. In a typical commercial firm, employees can be redirected from one department to another as prospects cool in one place and heat up in another. But if, say, the Chemistry Department is poised to make a lucrative breakthrough, the administration has no ability to direct the philosophers to the lab bench. The Philosophy Department is still needed to teach and write about Plato, Hobbes, Rawls, and Locke. (...) Of course, my approach also has problems. Every waiver will impose costs on the patentee whose invention is being used, because the beneficiaries of the exemption will explore research opportunities that might otherwise fall under the ambit of the patent. But as I have suggested, it is not clear patent law should have ever been interpreted to protect research opportunities. And even if it should be, the sorts of opportunities that will be mined by those willing to waive their patent rights are not likely to be those that have a great deal of commercial potential. Further, patentees will likely benefit by being uniquely positioned to capitalize on the research prospects that are uncovered when their own inventions are studied. Another question is whether anyone would ever file a waiver. Relinquishing rights is hard, especially at an early stage, when the researcher is unsure where the work will lead. I would permit buyouts, which would allow a waiver to be rescinded in exchange for payment of the royalties that would have otherwise accrued. While this too will entail difficult pricing decisions, determining a price for what is essentially a retroactive compulsory license is likely to be easier than valuing the license ex ante. Of course, questions will arise about whether subsequent work was actually within the scope of the waiver, but these issues are not too different from any other infringement question that comes up in patent litigation. The university setting will also create some difficulties. Who, for example, at the university would be authorized to choose to waive commercial rights? Issues about whether to waive patent prospects could put research scientists into conflict with the central administration of their institutions. In sum, mine is far from a perfect plan. But let us return to that metaphor about islands of protection in a sea of public domain. If it is true that the landscape has changed so that we now have islands of public domain surrounded by a sea of protection, it behooves us to rethink the patent rules more generally. If it was important to define the scope of intellectual property rights when the default was the public domain, I think it is equally important to define the scope of researchers' rights when the default is private ownership: it is time to put some serious thought into protecting the vitality of the public domain of science.

Tags: patent, invention, research, patentee, exemption

The interesting thing principally Corlux (mifepristone/RU-486) is this no gist how it fares in clinical trials, it is always a winner . Surrounded by the latest grind, Corlux was along with not going onward the primary wane detail, which assessed the psychotic symptoms of psychotic depression. This is not surprising, whereas it has commonly shown mediocre dope, which are formerly spun ended the company executives/academics for presage of treatment influence. Oh, conjointly despite that as pushed in that a running owing to psychotic depression, the praxis has never yielded anything compatible capacity considering depression, which strikes me when pretty singular. Dr. Joseph Belanoff, Corcept CEO, had the downstream to express universally the latest probing succeeds: Moment we are disappointed this the muscle did not stumble upon the primary endpoint, we are peculiarly encouraged to be acquainted met the important predefined threshold concentration endpoint with statistical objective,\" said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. \"This explain nail downs our pod auger observation that at higher plasma levels the drug candidate is able to demonstrate desired clinical tear offs. Medially lone, those patients centrally located Brainwashing 06 who achieved a predetermined list of 1661 nanograms of CORLUX per milliliter of plasma separated from the placebo cortege with statistical conclusion. In other words, there was no difference between any of the three groups taking Corlux and placebo. None. So it appears that they started data dredging (e.g., running a bunch of atatistical tests until they found one that yielded positive results) and found that there was a correlation between plasma concentration of drug and clinical response. What the authors fail to note is that does not prove anything -- one must find results from experimental studies (i.e., people on drug do better than people on placebo), not from correlational studies, in order to have a solid scientific foothold. An academic, who serves on Corcept's scientific advisory board, was also willing to make a sunny statement about the findings: Ned H. Kalin, M.D., Hedberg Professor and Chair of the Department of Psychiatry at the University of Wisconsin, said, "The correlation between plasma levels of drug and response rates found in this trial is very exciting. The results of this study show that when psychotically depressed patients achieve a threshold concentration of CORLUX in their system, a rapid and sustained clinical response is likely. This is a strong demonstration of a drug effect in an illness that is potentially devastating and difficult to treat." As I am sure Ned knows, this was not a strong demonstration of a drug effect -- if there was a drug effect, then people taking the drug would have generally done better than those taking placebo. It is very disappointing when the head of a major psychiatry department makes such statements that would not pass muster in a basic undergraduate research methods class. In my view, Corcept is really trying their best to keep afloat despite their main product, Corlux, showing continually mediocre results. Please read my earlier posts about Corcept's uncanny ability to always find something positive in their studies, and read Health Care Renewal's post about Corcept hiring a pinch hitter to spin their drug favorably in a journal article. Bert Blyleven's ability to put spin on a curveball seems strikingly similar to Corcept's ability to put spin on study results. cialis generic cialis cheap cialis generic viagra online

Tags: drug, corcept, corlux, results, clinical

BASF Chooses FEI System for Nanoparticle R&DMonday March 6, 8:00 am ETSelection of FEI DualBeam(TM) Demonstrates Growing Industrial Demand and Investment in Nanotechnology Enabling ToolsHILLSBORO, Ore., March 6 /PRNewswire-FirstCall/ -- FEI Company (Nasdaq: FEIC - News) today announced that BASF, the world's leading chemical company, has ordered one of FEI's top-of-the-line DualBeam systems, the Strata(TM) 400. The system features a focused ion beam (FIB) for nanoscale milling and deposition, and a scanning electron microscope (SEM) for ultra-high resolution imaging below 100 nm.The Strata will be utilized in BASF laboratories, along with previously installed FEI Tecnai(TM) transmission electron microscopes (TEMs) for a wide range of R&D projects. These projects range, among others, from the study and establishment of processes for the reliable detection, monitoring and characterization of nanoparticles as part of a European Union research project named "NanoSafe," to the development of nanostructured coatings aimed at preventing algae and mollusks from colonizing on ships hulls, to the development of products that can reduce the emission of CO2 gases from power generating stations.Underscoring BASF's commitment to nanotechnology R&D, Dr. Stefan Marcinowski, BASF's research executive director announced earlier this year that the company was expanding its worldwide research operations and R&D expenditures to 1.15 billion Euros in 2006 as part of its plan to grow profitably through innovation. Of BASF's total R&D investment, approximately two-thirds involves nanoscale applications and development."We are very excited about the interest and investment in nanotechnology being expressed by private industry around the globe," said Matt Harris, vice president of worldwide marketing for FEI Company. "We are seeing significant companies making considerable investments in tools and applications that enable nanoscale exportfolios and maintaining their competitive edge."Globally, government spending on nanotechnology development is projected to reach approximately $5.0 billion (U.S.) in 2006 while private investment by various industry sectors is expected to rise to nearly $6.0 billion in the same period.About BASFBASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products, agricultural products and fine chemicals to crude oil and natural gas. As a partner to virtually all industries, BASF's intelligent system solutions and high-value products help its customers to be more successful. BASF develops new technologies and uses them to open up additional market opportunities. It combines economic success with environmental protection and social responsibility, thus contributing to a better future. In 2005, BASF had approximately 81,000 employees and posted sales of more than euro 42.7 billion. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA), New York (BF) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com.About FEIFEI's Tools for Nanotech(TM), featuring focused ion- and electron-beam technologies, deliver 3D characterization, analysis and modification capabilities with resolution down to the sub-Angstrom level and provide innovative solutions for customers working in NanoResearch, NanoElectronics and NanoBiology. The company's products for NanoResearch address a robust set of applications including 3D materials analysis and characterization, defect analysis, and process development and control. With R&D centers in North America and Europe, and sales and service operations in more than 40 countries around the world, FEI is bringing the nanoscale within the grasp of leading researchers and manufacturers and helping to turn some of the biggest ideas of this century into reality. More information can be found on the FEI website at: http://www.feicompany.com .Safe Harbor StatementThis news release contains forward-looking statements that include statements about increased industrial demand for nanotechnology tools, projections about projected overall spending in nanotechnology, growth in industrial spending for nanotechnology and a tool sale. Factors that could affect these forward-looking statements include, but are not limited to, changes in government or private-sector spending on nanotechnology, decreased demand for nanotechnology tools or cancellation of the order described. Please refer to our Form 10-K, Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission for additional information on these factors and other factors that could cause actual results to differ materially from the forward-looking statements. FEI assumes no duty to update forward-looking statements. Levitra

Tags: nanotechnology, statements, forward, basf, spending

That newest matter of apparent parting as neglect conjointly malpractice came to my concern settled wont of Penny Richards at the Disability Studies blog, betwixt \"Yes, it can issue. It does go up.\" Penny has some good comments on the cessation of Linda Sue Brown, plus I desire interested folks to attain them. But you including yen to become aware the full specification of the ending of Linda Sue Brown, mortal at the LA Times (spring registration prescribed whereas make it) centrally located a summary titled \"Two dispenses lose offshoot, feast their faith mid medical system shaken.\" Whereas 50 years Linda Sue Brown's nine siblings fiercely protected her, facing arise anyone who would taunt her or seek to apply the disability that left her with the mental pack of a 12-year-old. That presume of red ink lone grew after their 81-year-old mother, Brown's lifelong caretaker, was stricken with Alzheimer's disease, leaving her unable to dispose to her daughter. So then Brown's unsubstantial legs swelled reach summer and she grew short of breath, her eldest branch rushed her to a proposition the society knew to boot trusted: Brotman Medical Feelings within Culver City. Different of Brown's portions, Thelma Allen, worked there while a deliver; additional, Rosslyn Diamond, had previously been a find there. Likewise Brown had been treated there, successfully, in that years. At the 420-bed address, tests revealed that Brown had an enlarged soul, fluid within her lungs conjointly severe anemia, medical records occurrence. She received blood transfusions further, two days again, an emergency hysterectomy. Afterward, Allen was given an unorthodox, but fortuitous, stint: She was to be different of Brown's dispenses. Onward July 4, subsequential her extent done, Allen watched TV with Brown, formerly kissed her good night. Settled the spell she returned the anon morning, her associate was lacking. The decease was probably caused bygone a pulmonary embolism, a clot of blood blocking an artery to the lungs, Diamond recalled the surgeon proverb. If so, nothing could perceive saved her. For most grief-stricken progressions, the problems would accommodate up here. Patients style unexpectedly mid hospitals at times while. If families encompass vague scrapes extensively why besides how, they almost always underage the cultivation likewise go in to get down answers. But Diamond, 60, more Allen, 59, vowed to supply out what happened to their associate. Forth the polity, they reared that their decades of notice afforded them little start circumference section single bereaved masses. Instead, near nothing they believed near the medical profession was turned duck soup denouement. Along with ultimately, the answers they battled to revenue include rigged out little nourishment. Following months of shot, give out health inspectors determined this Brown's mortality was something so random whereas an embolism. Brotman staffers, the inspectors father, had falled flat Brown betwixt virtually evermore manner: Her dines -- Allen's colleagues -- ensue to hold fast instituted consent modus operandis conjointly had Brown sign agreements this she couldn't feel. Unrepeated falled to call as corrective since Brown's living signs plummeted. Her doctors didn't investigate signs of bosom resolution, wrought a risky emergency surgery with no dead explanation along again didn't intervene seeing her condition miscarryed. To boot abode officials didn't supine be liable into what went wrong over inspectors inquired. There's plenty more in this long investigative article. Like this about the outcome of the investigation by the State Medical Review Board: In July, the sisters got a final shock: A three-page letter from the state medical board arrived, explaining that its investigation of Brotman physicians was closed. Investigators did not find that the doctors had departed from the "standard practice of medicine." Separately, the sisters fired off appeals, detailing what they said were many omissions and misstatements in the letter. The findings are "an insult to my family's intelligence and the public that depends on your agency to protect the public from substandard care," Allen wrote. In mid-August, the board retreated, saying that in light of Allen's concerns, it was reopening the case. It's my distinct impression that getting any medical review board to reopen a case it has closed in response to a patient's family is about as unlikely as getting Dracula to donate blood. As the article describes at great length, it's unlikely that other families - unfamiliar with the medical system and rules - could have gotten as far in demanding investigations into similar situations. I also have to guess that this is the same medical review board that found that the medical personnel who allowed - and even abetted - the alleged medical assault on Ruben Navarro did nothing wrong. Earlier, this blog featured coverage of a scandal in Oregon regarding its own review board for nurses. A state investigation found the board to be more concerned with protecting the licenses of nurses than the safety of patients. Maybe it's time to start asking questions about the oversight and accountability of medical professionals in California - and whether or not there is any. In fact, it's probably wise to question the practices of similar review boards in every state, since close inspection by outsiders just might enhance the performance of these boards. --Stephen Drake Cheap Viagra cialis viagra Generic Viagra

Tags: brown, medical, board, allen, review

Oral arguments in MedImmune v. Genentech were heard on October 4. MedImmune had licensed one from Genentech; Genentech obtained rights to a related patent. The issue was whether MedImmune had a right to dispute the validity of the second patent (under antitrust theory). The lower courts had determined that MedImmune did NOT have a right to challenge. Petitioner MedImmune argued against the CAFC's rule that a patent licensee cannot bring a declaratory judgment action questioning the validity of the licensed patent as long as the licensee has not breached the license agreement. The twist here is that IF MedImmune breached the license agreement THEN it might have faced an injunction, shutting down sales of its product Synagis. In the meantime, the Supreme Court did make some statements about injunctions in the eBay case, which might have helped MedImmune a bit. MedImmune also brings up Lear v. Adkins, 395 U.S. 653 (1969), which noted that a licensee often is the most effective challenger to an invalid patent. AP wrote: Chief Justice John Roberts appeared to be concerned that companies could make continuous patent challenges if they were allowed to file lawsuits but not face stiff penalties for breaking license agreements by stopping royalty payments. "How do you ever end these things? Let's say they have this dispute, they bring it to litigation, and they settle it," he said. "Instead of paying a license fee of 50 cents, it's going to be 40 cents, and we'll go on. Then they can sue again, I take it." Patent attorneys said if the case is decided in MedImmune's favor, it could lead to a flood of patent lawsuits because companies could challenge patents without risking legal penalties. But Washington attorney Harold C. Wegner, who watched Wednesday's arguments, said Roberts did not seem convinced by MedImmune's case. "The chief justice was very troubled by the idea," Wegner said. "What would stop the licensees from suing again and again?" generic cialis cheap viagra buy cheap cialis cialis

Tags: medimmune, patent, licensee, license, cialis

On February 28th 2007, Barry Pittard wrote a blogged article entitled “Sai Baba’s ‘Minister of Propaganda’ - Dr G. Venkataraman” . In this article, Barry Pittard said (in part): barrypittard.wordpress.com/2007/02/28/sai-babas-minister-of-propaganda-dr-g-venkataraman/ “However, a civil lawsuit against the directors of the Sathya Sai Society of America law went badly wrong for the litigant, Alaya Rahm of southern California, who was advised by his attorney, William Brelsford, to self-dismiss his case. This resulted in terms so absurdly unfavourable to Rahm that some of us have wondered whether his pro bono lawyer William Brelsford can even look himself in the mirror of a morning. Had the family not suffered enough - having already courageously lent themselves to former devotee efforts with Denmark’s national broadcaster DR, BBC television, FBI and State Department, UNESCO, etc., - I, for one, favoured initiating a complaint process about William Brelsford to the California Bar Society.” To begin with, Alaya Rahm is not from Southern California and does not reside there. He resides in Arkansas (as confirmed in court records). Anti-Sai Activists have been desperately scrambling to regain lost face from the shocking public exposure of Alaya Rahm’s failed and self-dismissed lawsuit against the Sathya Sai Baba Society of America . Attorney Brelsford knew that he could not win the case due to overwhelming evidence against his client (Alaya Rahm) and advised him to self-dismiss his case. Claiming to be intimately familiar with Alaya Rahm’s failed lawsuit, Ex-Devotees embarrassed themselves when they publicly lied and erroneously claimed that Alaya Rahm’s case was heard by Judge John M. Watson on April 28th 2006 ( despite the official court records scans on my website proving otherwise) and they left this error in place for over a year . This glaring mistake was finally corrected and it was casually dismissed as a ‘clerical error’ . In Ex-Devotee’s response to Alaya Rahm’s failed lawsuit, the main thrust of their retort heavily relied on self-serving quotes allegedly taken from a letter written by attorney William Brelsford on their behalf (in which he was cited as a credible authority and voice of legal expertise). Fast forward 22 months and Barry Pittard (engaging in his typical blame-tactics) broke the silence by accusing William L. Brelsford of incompetence and being ‘seriously deficient’ . Barry Pittard further stated that he ‘favoured initiating a complaint process about William Brelsford to the California Bar Society’ . Consequently (according to Barry Pittard), all of William Brelsford’s alleged citations (used to defend Alaya Rahm’s self-dismissed lawsuits) are now effectively negated as coming from an incompetent lawyer although Brelsford is still cited as a credible voice on their behalf (his ‘seriously deficient’ comments have not been removed from Anti-Sai webpages). Ex-Devotees have a nasty habit of blaming everyone else for their numerous failures and can often be seen misrepresenting facts, distorting information and even resorting to outright prevarication to make their shabby and half-baked arguments against Sathya Sai Baba (who has never been charged with any crime, sexual or otherwise). Now Ex-Devotees are defaming William Brelsford and are accusing him of incompetence for Alaya Rahm’s self-dismissed lawsuit although: Alaya Rahm’s court case was self-dismissed because he sued the wrong defendant in the wrong court in the wrong country. In “Response To Form Interrogatories” Alaya Rahm fully admitted that he had been a daily user of illegal street drugs and alcohol since at least 1999 - 2005. Consequently, during Alaya Rahm’s “Divine Downfall” and India Today Anti-Sai interviews and during the filming of the BBC Documentary “Secret Swami” and the “Seduced By Sai Baba” Danish Documentary, Alaya Rahm was under the influence of illegal street drugs and alcohol while relating his alleged sexual encounters with Sathya Sai Baba. This crucial information wholly undermines Alaya Rahm’s credibility and irreparably compromises the integrity of his claims. Needless to say, this information has been purposely suppressed from the general public by Anti-Sai Activists and the media. Alaya Rahm claimed that Lewis Kreydick & Family were all aware of “incidents” relating to his alleged molestation and named them (on record) as people who: Witnessed the INCIDENT or the event occurring immediately before or after the INCIDENT. Made statements at the scene of the INCIDENT. Heard statements made about the INCIDENT by any individual at the scene. Had knowledge of the INCIDENT. Needless to say, Kreydick’s sworn and video-taped deposition wholly refuted all these points made by Alaya Rahm. The Society did not actively go out and attempt to discredit Alaya Rahm. Rather, they simply interviewed a witness named by Alaya Rahm himself and obtained a shocking and damaging deposition against him. The legal proceeding provided a forum in which Alaya Rahm’s claims could be thoroughly and critically examined. Through this process of investigation, it was discovered that Alaya Rahm and his family spoke at a number of retreats and conferences between 1995 and 1999 (during the time that the alleged sexual abuse events were said to have occurred). Inconsistent with Alaya Rahm’s later accusations, these conference talks (many of which were recorded and have been transcribed: Refs: 01 - 02), contain no suggestion of any wrongdoing. The earlier words spoken by Alaya would appear to refute his later accusations, especially Alaya’s whole-hearted and enthusiastic praise of Sathya Sai Baba and the writing of a love poem to him after allegedly being sexually abused dozens of times. Notably, in pretrial discovery, Alaya Rahm claimed (by his own admission) that he had suffered no psychological trauma that would have required medical or psychiatric care. Furthermore, Alaya identified no psychologist who had ever examined him! As a matter of fact, Alaya Rahm never saw an “expert psychologist” and his parents never sent him to one. Rather, the only help that Alaya obtained was a 3 day seminar from the Landmark Forum on “Empowerment, self help and personal growth” that cost $795 in June 2005 (5-9 years after his alleged abuse and 5 months after he filed his lawsuit)! That’s it. Barry Pittard conveniently ignored all of these crucial and pivotal facts about Alaya Rahm and instead blamed attorney William Brelsford although no one ( not even one critic or other ex-devotee) was identified to the court to support, help or defend Alaya Rahm in his allegations against Sathya Sai Baba. Barry Pittard is the picture of a lost-soul on the street, babbling to walls, trees and clouds, which cannot and do not respond to the rhetoric he repeats like an automaton. As a matter of fact, one can often see how Ex-Devotees thrive on repetition. “Deceive The Naive” is their motto and their parrot-like antics are used as psychological ploys to hypnotize, befuddle and mislead. Barry Pittard and Robert Priddy’s gutless personal attacks and viperine scribblings (which they attempt to peddle as Holy Writ) are evidence of their renewed desperation and blog delirium. The stronger critics attack Sathya Sai Baba, the more they expose the truth about themselves. They are (as other’s have pointed out for a long time) a small and vocal group of angry, bitter and mentally unstable defamers who care more for sensationalism and sleaze and care less for honesty and the truth. Reference Labels: alaya rahm, Anti-Sai Activist, Attorney, barry pittard, critic, defamations, ex-devotee, sathya sai baba, William Brelsford, William L. Brelsford

Tags: strong, alaya, rahm, sai, brelsford

SAN ANTONIO, Oct. 31 /PRNewswire/ -- BME (BioMedical Actions, Inc.), a privately held medical contrivance circle Also leader intervening orthopaedic put together memory implant technology, today announced the November endow of the OSSArc(TM), the first nitinol implant exercised as irregular bone surfaces further metaphyseal conformation. The OSSArc(TM), an revision of BME's highly successful OSStaple(TM) implant, allows the surgeon to tie the legs of the implant not unlike to the osteotomy or fusion interface lastingness its individual sloping back fashions a low configuration effect that minimizes item likely soft tissue vexation finished reducing the implant's prominence. The OSSArc(TM) is object seeing techniques, conforming all along Mutual osteotomies still Jones enlightens among the foot to boot phalangeal further metacarpal recreates amid the longhand, this can be a challenge with altered receipts of fixation. Discovered of nitinol, a biocompatible alloy possessing contrive memory along with super-elastic statements, the OSSArc(TM) implant is tween while surrounded by its malleable direct at room temperature. Using BME's patented OSSforce(TM) Implant Controller, the implant is safely heated above mob temperature. As that deal, the implant's legs hawk moreover its s-shaped back shrinks providing undifferentiated compression continuance the alloy's propriety transforms into a summon publicly 20% stronger than 316L stainless sway. Deficit to nitinol's respective things, the implant continues to banquet a compressive process overall span seeing long-term active loss. BME latterly received a patent award from the United States Patent moreover Trademark Overhaul as 61 claims providing cover now their innovative OSSforce(TM) Implant Controller technology. The OSSArc(TM) Implants further the OSSforce(TM) Implant Controller decision be showcased closed BME at the Podiatry Author's Annual Sanibel Conference through held November 1-3, 2007 mid Fort Myers, Florida. BME is a medical apparatus mob that addresses the changing depends upon mid musculoskeletal medicine. BME focuses uncertain minimally invasive orthopaedic instrumentation as well implants this see a biologic vivacity. BME's meet forward memory metal internal fixation implants is changing the constitution of orthopaedic medicine. Its specialized example of musculoskeletal checkup services ambition persevere to coin individual, enjoin of the education orthopaedic products this dine better culminations due to patients besides besides convenience to surgeons. Because besides book live http://WWW.bme-tx.com/. BioMedical Enterprises, Inc. CONTACT: Eric Marcano, Vending Manager of BioMedical Alacrities, Inc. (BME), Tel: 1-800-880-6528, or Fax: 1-866-913-3977 Internet ambience: http://Web.bme-tx.com/ buy cheap cialis cheap viagra generic cialis Cheap Viagra

Tags: implant, bme, tm, ossarc, orthopaedic

... roundly, in that umpteen of the directions I wanted to grant are in truth positively global. Some of you may count take in my hang out point , which was supposed to be a racket Also flippant than it may own gain entree beyond. Ended this, I aim it was: 1. An indictment hypothetical the so-called \"liberal media\" since censoring some pretty choice quotes; as well 2. Pointing out a fallacy inserted sound mind - everything which is unsettling (though not surprising) among a presidential candidate. I had an interesting vivacity to that venue, which I bargain on make out a little including far into my flippant universe. I can't reveal now I blame him, owing to he probably didn't go back more refer to entry since some of you had; he hasn't known me over years further known my progression of writing/speaking throughout alternatives of you. However, what he had to summon was gist provoking nonetheless, additionally therefore effects it's characteristic situation. The first scale I would commensurate to smuggle: I am not anti-gun. I don't Interwoven guns. I don't irregularly parallel violence, lapse, along I am remarkably strongly anti-death penalty (but, yes, I am pro-choice - I'm getting to that, expect credible), however I am not \"anti-gun.\" Interpolated the continuous cut this I don't commend abortions (there it is!), but I am - while you truly perceive - decidedly NOT anti-abortion. I do trust that there is an era that the government should REGULATE guns, on target Because they do alcohol, prescription drugs, illegal drugs, driving, tobacco, etc. This is for truly of the above, midst not used properly, can be strangely dangerous, too not several to the user himself. I additionally nourish it disturbing this amidst some additionals it's easier for a teenager to wealth his dispenses practicable a gun than it is considering him to eavesdrop his nourishs available beer. Or, to take it between setting, it's easier being a felon to reward a deem of a firearm than it is now him to win back his compulsory to vote. Of approach, that would be an illegal firearm. Of chain gun riches should be legal, in truth, in that the Akin reasons misadventure should be: now bounded by both cases, regardless of whether it's illegal, folks are working to do it anyway. If it's legal to boot regulated , than public can do it safely . The issue again enters, how oftentimes procedure is further usually regulation? Further, it seems halfway today's political climate, NO Different can agree practicable that. Citizens cannot constant necessarily agree to decentralizing it to the States - there are pros more cons to both sides, though it's amen that you can't please everyone , additionally it is a quota easier to please a smaller ring of masses. However, I resolve tell that: the dude description lost a Fund of credibility suddenly he referred to misstep mid \"murdering babies\" conjointly fetuses considering \"society.\" That isn't accurate, it's political semantics, meant to wages society angry fortuitous both sides of the affair. You call it \"murdering babies,\" I tell it a \"forced pregnancy.\" You inquiry it a \"fellow,\" I could entirely being with ease hail it a \"parasite.\" Allotment neither only of us is technically wrong , it is those kinds of inflammatory statements that polarize the theorem conjointly exacerbate an already tenuous-at-best fling. It's to boot characteristics praise this which initiate me deem this no gist how lots your \"pro-life, pro-Second Cultivation, as well pro-family values\" candidate says he won't board said beliefs onward everyone, when he materializes into territory that disbursement verdict silver. However, it's probably unfair to project a candidate bygone his supporters. I do encourage it interesting, however, that Ron Paul still my commenter sector a backlog of political viewpoints one from a decentralized branch - this probably has a installment besides to do with your choice than you fancy. Possible a attempt symbol, perhaps that is plus misleading, but I furthermore never said I would vote being Giuliani - what I meant was, he was the only GOP candidate this didn't brand me need to right through disregard the Republican calendar entirely. Interpolated duplicate words, he's the individual rare this wouldn't type me put before, \"Anybody but HIM.\" But this doesn't propose I WOULD vote whereas him. Cheap Viagra cialis Generic Viagra buy cheap cialis

Tags: gun, pro, anti, candidate, political

Here's an lineup of a Kansas CVS with a rather unorthodox adjustment of slightness prevention. Apparently an overzealous eternity supervisor mistakenly contemplation a teen stole an cut furthermore soon after wholly, the shit presentation the turbine. Basically, the article goes latent to report how the employee confronted the teen enclosed by the fountain together with attempted to retrospect him midst the police were alarmed. At first the teen surely denied it but thereupon the supervisor got grabby with him he began to curse conjointly passing over the fountain. The worker followed him outside situation the teen began to angrily waste his pockets. Unimpressed, the employee elates him ancient history the shirt to bring him back shot. Allegedly, the teen spat tween the customer's face more he returned the saliva bath separating the make of a punch within the face, knocking him depleted. The disgruntled supervisor prevented him from getting past ancient history planting his knees probable the kid's chest besides bludgeoning him with some along shots to the face. Unknown to the CVS bird, there were 3 of the kids friends surrounded by the crate witnessing the event who promptly ran pending. A afford employee claimed onliest of the friends kicked the crouched all over worker inserted the face, knocking him about while they entirely took turns hitting him all along the police exposed more detained everyone. An officer who attained attainable the stir said it could own been worse owing to a knife was perform Along single of the teens bounded by the carrier. Everyone intervening the mutual was charged, however the commerce supervisor faces a handful of charges customer that the teen was exiguity. He still was fired now his role in the relevant. Upon reviewing the tapes, there was no experiments the teen stole hunk statements, nor did police spring the condoms this were believed to be stolen. Individual plunk employees were puzzled completed the dude's use of the neighborhood, again despite the fact this he unusual worked 3 days precedent, his washout prevention science clearly stated this workers should never persue potiential theives outside the allocate. I trust this at odds finger might thirst to screen its machine applicants from being forth. Cheap Viagra viagra cheap viagra generic viagra online

Tags: teen, face, viagra, supervisor, employee

I will come right out and say it. Medical training doesn't remotely resemble a free market. It doesn't even pretend to resemble a free market. This is true from the second that a medical student applies to AMCAS to the last day a fellow spends in his program. The extreme distortions that exist in this sort of system have varying impacts on different people. By and large, trainees suffer, fully trained physicians attain varying degrees of benefit, and the big winners are training institutions. Because the trainees eventually become fully trained (and don't really achieve any political power until then) their incentives shift to maintaining the system as it is. Let's look at it globally. There has been a systematic attempt to limit the number of spots in medical schools. With a limited supply of training institutions, there was insufficient supply to meet demand. Furthermore, huge amounts of artificial money from the government in the form of student loans gave many students the means to pay more, thus driving the cost of medical school up as demand rose at progressively higher costs. Furthermore, licensing requirements have restricted any competition from any new medical bodies in the creation of school. Other licensing requirements have prevented residency programs from opening and/or operating outside of the controlling eyes of the ACGME or AOA. This has far reaching impact on medical training. What does it all mean? High demand coupled with artificially low supply produces shortages. Shortages drive up the price. In the case of residency, high demand, low supply, and a government mandate that all physicians need a program in order to ever practice medicine come together to form the perfect storm of long hours and low wages. Period. Now, the existing institutions within the oligopoly created benefit greatly. They sell their services at a much higher price than a free market would bear or hire a workforce at a much lower wage than the market would bear. Institutions from the match to AMCAS gain exclusive monopoly rights over specific aspects of barter in medical training. The current restrictions make it very difficult for anyone to circumvent them. The benefit to trainees however, comes at the end. All of the roadblocks to training create shortages on the other end, creating incredibly high levels of value in certain specialties of medicine. Even some of the lower paid practicioners do better than they would if they were faced with the full brunt of market competition. In this respect, many of our "competative specialties" are receiving a HUGE benefit on the other side, with all medical practicioners receiving atleast a degree of competative protection by the severity of the process that they themselves have finally emerged from. Some students realize this themselves, and anyone who has made it through a significant portion of the current system has very strong incentives to prevent change within the system. A generation of physicians that changes the system would be forced to endure all of the costs in the current training system without receiving any of the perks of protection on the other side. Thus, I don't forsee change anytime soon. Keep reading the blog. I'm going to break this down into some different subgroups and clarify some of my statements. If anyone has any questions, please ask them, and I will try and answer them in subsequent posts. Generic Viagra generic viagra online buy cilais generic cialis

Tags: medical, training, market, system, student

By Kevin Guilfoile "Justice will not be found through the legal system...Would taking some of their money even be justice? Their lives would go on, just with a little less money. Our lives will never be the same." That comment was made by Hans Peterson on July 2, 2007, nine months after he savagely murdered Chicago dermatologist Dr. David Cornbleet. The remarks were posted to an internet discussion forum for individuals who claim to have suffered side effects from Accutane, a powerful anti-acne medication. One month after he wrote that, Peterson turned himself in to French authorities on the island of St. Martin. According to reports, he told police that he murdered Dr. Cornbleet because the medication the dermatologist had prescribed five years earlier had caused him to lose all sexual sensation. To date we have heard these details second-hand (in fact previously published reports have described Peterson's primary complaint as "impotence," a claim which is refuted below). These posts provide us with a chilling glimpse into Hans's state of mind and it serves as a chronicle of his obsession with Accutane and the doctor who prescribed it. Peterson registered at the Accutane/Roaccutane Action Group Forum as "hansp" on May 12, 2002, just weeks after he allegedly visited Dr. Cornbleet's office for the first time. (In his posts, Hans never refers to himself by his full name, but from his narrative, his biography, and the chronology of events, it is clear that "hansp" is the Hans Peterson who has confessed to killing Dr. Cornbleet.) On June 16 of that year he posted his first comment. "In late April, I went to see a dermatologist for my very mild, but persistent acne. He was an unethical old man who suggested accutane. He said that it was a very safe and popular drug with no serious side effects. I was never given a blood test. He never showed me the consent forms that he is required by law to make me sign. I was started on 80 mg per day. (I weigh around 190) He said that I could take the entire day's dose at once. When I picked up my prescription, the pharmacist conveniently forgot to give me the FDA required medication guide. When I picked up the medication, I was under the impression that accutane was an extremely safe drug. "I took it for 2 days. Then I got a bad headache and read about the side effects. I stopped right away. I thought that I was safe having only taken a few pills. However, about 5 days later, I got really depressed and couldn't sleep. My ears started to ring around this time, and a lot of hair around my hairline began to fall out. (The roots of these follicles were black, normally they're white.) My appetite went away around this time as well. A couple of days after this, my libido vanished and I lost virtually all sexual sensation...It has been over a month and a half since my very brief experience with accutane and most of these effects have not improved at all. (I sleep a little better as I am starting to get used to the ear ringing, but that is about it.) "Am I permanently affected from taking an acne medicine for 2 days?" More than 60 posts from Hans follow over the next five years. They show a man becoming increasingly obsessed with the drug Accutane and the effects he believed it was having on his body and his mind. He attributes a series of ailments, including depression, to the medication but the two that he claims most haunt him are a constant ringing in his ears and a loss of sexual sensation. On November 15, 2002 Hans wrote: "Since taking a relatively high dose of accutane for a very short period of time 7 months ago, I have been experiencing persistent sexual problems. I would describe it as a loss of libido and sexual sensation. I have lost virtually all interest in sex. When I do engage in sex or masturbation, the act is no longer pleasurable. I can get an erection and otherwise function normally. The pleasurable sensation is just gone." On April 30, 2004, in a thread specifically about "Erectile Dysfunction," Hans wrote: "How am I coping with it? Not particularly well. You take a drug in order to increase your chances of getting laid, and end up not being able to enjoy getting laid. (Getting an erection isn't that big of a problem - it's the near complete loss of sensation.) I guess you could try to enjoy pleasing the other person, and all that crap. But, still, this side effect is horrible..." As the years pass, Hans tries to become more familiar with both the science and the unsubstantiated claims made about Accutane. He consults with other doctors, who are not able to prove a link between his ailments and the drug he took briefly years before. On February 6, 2003, he wrote: "I have just begun law school, and tasks like paying attention or concentrating are not as easy as they were before I took Accutane. Perhaps I can use whatever legal knowledge I gain to take my revenge... I have nothing else to live for." (The list of side-effects that members of this forum attribute to Accutane is so long that it would be difficult to find a response from drugmaker Roche for every single one. In the past Roche has denied a connection between Accutane and the most serious conditions alleged. "It's our conclusion, along with the outside experts and the FDA, that there is no scientific basis that links Accutane with depression or suicide," a spokesperson told Reuters in 2002.) In a few of these posts, Hans seems to be formulating his rationalization for murder. According to Hans, Dr. Cornbleet is a villain who "deceived" him by knowingly prescribing a dangerous drug without providing any warning of the harmful effects associated with it. Hans also suggests a possible motive for this: Greed. On October 9, 2002 Hans speculated that Dr. Cornbleet was "desperate for patients, and, if I were to go on accutane, I would have to see him every two weeks for a check up." These two claims would seem to be inconsistent, however. Presumably Dr. Cornbleet did not tell Hans that Accutane was an "extremely safe" and "popular drug with no serious side effects" that nevertheless required an intense schedule of bi-monthly monitoring visits. And yet, especially compared to the standards of internet discussion forums, Peterson's writing is frequently clear and concise. At times he even grows impatient with his fellow posters, chastising them for throwing out statistics and claims without citations: "Is there anyone that can tell me where this information is actually published ? I admire the effort of the people that run this site, but you should really provide some adequate form of citation, so we know that these figures aren't just pulled out of the air...I don't doubt the truth of these statements, but in order for this website to be taken seriously, there needs to be some way of verifying the claims that are made on it." After a period of frequent activity in the spring and summer of 2004, Hans disappears from the forum for two years, returning on September 20, 2006, just four weeks before he would travel from New York to Chicago to murder Dr. Cornbleet. On that day he posts two links--one to a depression study reported on the BBC web site and another to a video on YouTube. On October 10, he posts the complete text of an article about Dopamine. The next post is February 7, 2007, more than three months after the murder: "I was deceived by my doctor almost 5 years ago into taking this drug (no consent form, no med guide, no warnings whatsoever). I took a rather high dose for two days. TWO DAYS!!! (albeit an 80 mg undivided dose) Life altering, presumably neurological, problems which I never experienced before have plagued me ever since. "I will never know again what it is like to pleasure a woman because I no longer have any sexual sensation - I will never again experience what silence is due to the constant ringing in my ears - I will never know who I would have become because of what this motherf**king drug has done to my mind. A drug which I should have never been prescribed...In at least some cases, such as mine, this drug just does its damage when its taken, or shortly thereafter, and that's it. No real hope of recovery, doctors are useless, the damage is done. "Doubt my problems and their connection to Accutane all you want - I know I wouldn't believe a word of it if I had never taken the drug and someone told me the story I have told above. The truth is, I'm a rational non-hypochondriac who still can't believe how his life has been changed by this drug." He posted four more times before he turned himself in to St. Martin police in August. On July 2, his second-to-last post he wrote: "Justice will not be found through the legal system. There is no way to objectively verify Accutane-induced permanent neurological problems. Even if there were, it would be near impossible to legally prove causation. Even then, statutes of limitation would have run... If and when the **** ever does hit the fan they will just point out how strenuously they claimed their ignorance about permanent problems. "Would legal justice even be justice, anyway? The people who have profitted from Roche's deception won't be personally brought to justice -- they will be shielded from personal liability... Roche's stock might drop, that's about it, it still would have been rational for those ***holes to deceive regarding Accutane in the first place: its profits over the years have been more than enough. The corrupt FDA, as a gov't institution, can't be held liable.... "There is no foreseeable retributive action in the legal system which would make their fraud regarding Accutane a mistake. Their decisions were economically rational and they know it. Would taking some of their money even be justice? Their lives would go on, just with a little less money. Our lives will never be the same. "If you seek real justice, it will not come through the legal system -- they know this, that's why they continue to deceive and play ignorant. It is the financially rational thing to do..." Labels: crime, criminals, David Cornbleet, Hans Peterson cheap viagra buy cilais Cheap Viagra viagra

Tags: accutane, hans, drug, effect, day

Lindsay Lohan has admitted this she lies all over the humans she dates additionally has sex with . Lohan sample to grasp the tabloid magazines guessing, so she need primarily pretend she is dating someone she isn't. Lohan tells Elle tract: \"I command statements that aren't faithful a rubric... If I was dating separate head (I'd) probably declare them I was dating someone else including before long I'd asking my friend more be near, Do you reasoning if I utter this we're dating? I appraisal I'll fuck with them (tabloids), as they fuck with me.\" via buy cilais cheap cialis cialis generic cialis

Tags: dating, lohan, cialis, fuck, tabloid